Antibody ID	ANI0KLWUW
Antibody Name	Anti-B7H3 mAb 2E3-02
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	CD276 antigen (CD276)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.71%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Esophageal squamous cell carcinoma PDX model (PDX: ES0204)
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.88%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Prostate cancer PDX model (PDX: PR9586)
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.20%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Prostate cancer PDX model (PDX: PR9586)
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.11%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Prostate cancer PDX model (PDX: PR9586)
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Esophageal squamous cell carcinoma PDX model (PDX: ES0204)
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Esophageal squamous cell carcinoma PDX model (PDX: ES0204)

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 78.90%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.20%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.62 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.86 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.85 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.62 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.43 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	15.8 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	21.13 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	23.56 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 31.90%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.50%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.33 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.35 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 36.64%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 38.29%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54.06%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 68.25%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.60%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	33.14 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	33.49 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73.17%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.28%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	31.67 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	34.15 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.75 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	22.48 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.02 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.18 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.93 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.07 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.03 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	18.38 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.35 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	19.58 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	21.07 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.83 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	24.42 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	27.86 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	28.49 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	28.79 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	28.51 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29.16 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.43 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.9 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	32.47 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	42.07 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	83.36 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.8 nM	Positive her2 expression (her2+++/++)
Method Description	NCI N87 5000cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added, the maximum concentration of the drug is 1000 nM with a 4-fold dilution across 10 points, for the various ADCs. Cell proliferation was measured after 4 days exposure, 50ul Cell titer glo to test IC50.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Ref 1	Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.
Ref 2	Multi-payload antibody-drug conjugates and their preparation methods and uses